Health ❯ Healthcare ❯ Adverse Events

Treatment Safety

Giredestrant and Everolimus Clinical Outcomes

Epcoritamab Added to R2 Yields Large Efficacy Gains in Relapsed Follicular Lymphoma

Newly released results detail a chemo-free, outpatient regimen poised to reset second-line care.

Roche’s Giredestrant Plus Everolimus Extends PFS in Phase 3 evERA for ER-Positive, HER2-Negative Breast Cancer